Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Antiparkinsonian or Stimulant or [[:Category:NSAIDs|NSAID (naproxen)]]

Use the filters below to narrow your results.

generic:
brand:
None (43) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Benzedrex (1) · Cogentin (1) · Comtan (1) · Dostinex (1) · Eldepryl (1) · Neupro (1) · Ongentys (1) · Parlodel (1) · Sinemet (1) · Symmetrel (1) · Tasmar (1) · Treximet (1) · Xadago (1)
classes: (Click arrow to add another value)
mechanism:
Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Irreversible selective MAO-B inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)
uses:
None (59) · '"`UNIQ--vote-000015D0-QINU`"' (1)
starting dose:
None (59) · 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours (1)
preparations:
None (59) · 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric) (1)
fda max:
None (59) · 2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache (1)
routes:
None (59) · Oral (1)
onset:
None (59) · Headache relief at 30-60 minutes (1)
duration:
None (59) · 4-8 hours (1)
halflife:
None (59) · Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"' (1)
bioavailability:
None (59) · Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' (1)
pregnancy:
None (59) · Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (59) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' (1)

Showing below up to 60 results in range #1 to #60.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"